Intravenous Insulin in Patients With Diabetes After Percutaneous Coronary Intervention (PCI)

Intravenous Insulin for 24 Hours in Patients With Diabetes Mellitus Submitted to Percutaneous Coronary Intervention With Stent: Effects Upon Oxidative Stress and Inflammatory Markers

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00967642

Enrollment

Registered

2009-08-28

Start date

2006-08-31

Completion date

2009-04-30

Last updated

2009-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Percutaneous Coronary Intervention

Keywords

Patients with Diabetes Mellitus Submitted to Percutaneous Coronary Intervention with Stent

Brief summary

The purpose of this study is to evaluate the effects of intravenous insulin/24 hours to normalize glycemia upon markers of oxidative stress (protein oxidation and total antioxidant defense) and inflammation (C-reactive protein (CRP) and sCD40L) in diabetic patients submitted to PCI with stent.

Interventions

DRUGIntravenous Insulin

continuous intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with Diabetes Mellitus submitted to Percutaneous Coronary Intervention with Stent bare metal * Age: 18-80 years old

Exclusion criteria

* Restenosis * Drug elution stent * Acute coronary syndrome at last 30 days * Use anti inflammatory, antibiotic, vitamin E * Inflammatory disease or oncologic

Design outcomes

Primary

Measure	Time frame
Reintervention, Myocardial Infarction, Cardiovascular Death	6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026